肿瘤细胞治疗研究
英文原题：Clinical utility of CAR T cell therapy in brain tumors: Lessons learned from the past, current evidence and the future stakes.
嵌合抗原受体（CAR）T细胞疗法在血液系统恶性肿瘤中前所未有的临床成功，促使研究人员研究其在实体瘤中的作用。
嵌合抗原受体（CAR）T细胞疗法在血液系统恶性肿瘤中前所未有的临床成功，促使研究人员研究其在实体瘤中的作用。尽管其在实体瘤尤其是神经母细胞瘤中的应用已开始显现，但其在其他实体瘤如骨肉瘤或胶质瘤中的疗效的临床前研究已引起肿瘤学家的关注，值得在临床试验中尝试。恶性高级别脑肿瘤如胶质母细胞瘤或儿童中线胶质瘤，是常规可用疗法最难管理的恶性肿瘤之一，而复发性胶质瘤由于治疗选择有限，预后仍然最为黯淡。CAR T细胞等创新疗法可能通过改善预后并减轻现有疗法的毒性，为治疗肿瘤学家提供额外的助力。此外，CAR T细胞疗法有潜力在不久的将来被整合到侵袭性胶质瘤的治疗范式中。在这篇综述中，我们讨论了在脑肿瘤中使用CAR T细胞疗法所面临的挑战，列举了针对不同脑肿瘤的不同类型CAR T细胞疗法已完成和正在进行的临床试验，特别强调胶质母细胞瘤，并讨论了CAR T细胞在脑肿瘤中的未来作用。
The unprecedented clinical success of Chimeric Antigen Receptor (CAR) T cell therapy in hematological malignancies has led researchers to study its role in solid tumors. Although, its utility in solid tumors especially in neuroblastoma has begun to emerge, preclinical studies of its efficacy in other solid tumors like osteosarcomas or gliomas has caught the attention of oncologist to be tried in clinical trials. Malignant high-grade brain tumors like glioblastomas or midline gliomas in children represent some of the most difficult malignancies to be managed with conventionally available therapeutics, while relapsed gliomas continue to have the most dismal prognosis due to limited therapeutic options. Innovative therapies such as CAR T cells could give an additional leverage to the treating oncologists by potentially improving outcomes and ameliorating the toxicity of the currently available therapies. Moreover, CAR T cell therapy has the potential to be integrated into the therapeutic paradigm for aggressive gliomas in the near future. In this review we discuss the challenges in using CAR T cell therapy in brain tumors, enumerate the completed and ongoing clinical trials of different types of CAR T cell therapy for different brain tumors with special emphasis on glioblastoma and also discuss the future role of CAR T cells in Brain tumors.
MEMBER ACCOUNT
登录成功会直接打开下一页。
